1.Prognostic Value of Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (bFGF) Expression in Resected Non-small Cell Lung Cancer.
Seung Joon KIM ; Jung Mi LEE ; Jin Sook KIM ; Ji Young KANG ; Sang Hak LEE ; Seok Chan KIM ; Sook Young LEE ; Chi Hong KIM ; Joong Hyun AHN ; Soon Seog KWON ; Young Kyoon KIM ; Kwan Hyoung KIM ; Hwa Sik MOON ; Jeong Sup SONG ; Sung Hak PARK ; Seok Hwan MOON ; Yeong Pil WANG
Tuberculosis and Respiratory Diseases 2008;64(3):200-205
BACKGROUND: Tumor angiogenesis plays an important role in tumor growth, maintenance and metastatic potential. Tumor tissue produces many types of angiogenic growth factors. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have both been implicated to have roles in tumor angiogenesis. In this study, the expression of tissue VEGF and bFGF from non-small cell lung cancer (NSCLC) patients were analyzed. METHODS: We retrospectively investigated 35 patients with a histologically confirmed adenocarcinoma or squamous cell carcinoma of the lung, where the primary curative approach was surgery. An ELISA was employed to determine the expression of VEGF and bFGF in extracts prepared from 35 frozen tissue samples taken from the cancer patients. RESULTS: VEGF and bFGF concentrations were significantly increased in lung cancer tissue as compared with control (non-cancerous) tissue. The VEGF concentration was significantly increased in T2 and T3 cancers as compared with T1 cancer. Expression of VEGF was increased in node-positive lung cancer tissue as compared with node-negative lung cancer tissue (p=0.06). VEGF and bFGF expression were not directly related to the stage of lung cancer and patient survival. CONCLUSION: Expression of VEGF and bFGF were increased in lung cancer tissue, and the expression of VEGF concentration in lung cancer tissue was more likely related with tumor size and the presence of a lymph node metastasis than the expression of bFGF. However, in this study, expression of both VEGF and bFGF in tissue were not associated with patient prognosis.
Adenocarcinoma
;
Carcinoma, Non-Small-Cell Lung
;
Carcinoma, Squamous Cell
;
Enzyme-Linked Immunosorbent Assay
;
Fibroblast Growth Factor 2
;
Humans
;
Intercellular Signaling Peptides and Proteins
;
Lung
;
Lung Neoplasms
;
Lymph Nodes
;
Neoplasm Metastasis
;
Prognosis
;
Retrospective Studies
;
Vascular Endothelial Growth Factor A
2.Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients.
Yoon Ho KO ; Myung Ah LEE ; Yeong Seon HONG ; Kyung Shik LEE ; Hyun Jin PARK ; Ie Ryung YOO ; Yeon Sil KIM ; Young Kyoon KIM ; Keon Hyun JO ; Young Pil WANG ; Kyo Young LEE ; Jin Hyoung KANG
The Korean Journal of Internal Medicine 2007;22(3):178-185
BACKGROUND: Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is significant toxicity with this therapy. Therefore, a weekly schedule has been explored in several previous trials. In this retrospective study, we compared the efficacy and safety of a weekly schedule and a 3-week schedule of docetaxel monotherapy in a second-line setting. METHODS: Docetaxel was administered as 75 mg/m2 on day 1 every 3 weeks or as 37.5 mg/m2 on day 1 and 8 every 3 weeks until disease progression or severe toxicity developed. RESULTS: From October 2003 to March 2006, a total of 37 patients received docetaxel monotherapy and 36 patients could be evaluated. A total of 135 cycles were administered and then evaluated. The median overall survival was 13.3 months (95% confidence interval: 6.3~20.3) for the weekly schedule and 10.7 months (95% confidence interval: 8.3~13.0) for the 3-week schedule (p=0.41). The median time to progression was 3.0 months (95% confidence interval: 1.9~4.0) and 2.8 months (95% confidence interval: 1.0~4.6), respectively (p=0.41). The response rate was 16.7% for the weekly schedule and 21.1% for the 3-week schedule. The major form of hematologic toxicity was grade 3-4 neutropenia (3-week: 38.9%, weekly: 9.5%). The non-hematologic toxicities were similar between the two schedules. There were no treatment-related deaths. CONCLUSIONS: A docetaxel weekly schedule was very tolerable and it had comparable activity to that of the 3-week docetaxel schedule. Considering the efficacy and tolerability, a docetaxel weekly schedule can be an alternative schedule for the standard treatment of NSCLC in a second-line setting.
Adult
;
Aged
;
Antineoplastic Agents/*administration & dosage/adverse effects
;
Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
;
Drug Administration Schedule
;
Female
;
Humans
;
Lung Neoplasms/*drug therapy/pathology
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Retrospective Studies
;
Taxoids/*administration & dosage/adverse effects
;
Treatment Outcome